ID   CHFR_HUMAN              Reviewed;         664 AA.
AC   Q96EP1; A6NEN5; B4DZ77; B4E2L6; Q96SL3; Q9NRT4; Q9NT32; Q9NVD5;
DT   02-FEB-2004, integrated into UniProtKB/Swiss-Prot.
DT   02-FEB-2004, sequence version 2.
DT   10-MAY-2017, entry version 155.
DE   RecName: Full=E3 ubiquitin-protein ligase CHFR;
DE            EC=2.3.2.27 {ECO:0000269|PubMed:11807090, ECO:0000269|PubMed:11912157, ECO:0000269|PubMed:14562038, ECO:0000269|PubMed:18172500, ECO:0000269|PubMed:19182791};
DE   AltName: Full=Checkpoint with forkhead and RING finger domains protein;
DE   AltName: Full=RING finger protein 196;
DE   AltName: Full=RING-type E3 ubiquitin transferase CHFR {ECO:0000305};
GN   Name=CHFR; Synonyms=RNF196;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY,
RP   AND VARIANT MET-580.
RX   PubMed=10935642; DOI=10.1038/35019108;
RA   Scolnick D.M., Halazonetis T.D.;
RT   "Chfr defines a mitotic stress checkpoint that delays entry into
RT   metaphase.";
RL   Nature 406:430-435(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2; 3 AND 4), AND
RP   VARIANT MET-580.
RC   TISSUE=Teratocarcinoma, Testis, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT
RP   VAL-497.
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 359-664.
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, AUTOUBIQUITINATION, AND MUTAGENESIS OF
RP   ILE-306 AND TRP-332.
RX   PubMed=11807090; DOI=10.1083/jcb.200108016;
RA   Kang D., Chen J., Wong J., Fang G.;
RT   "The checkpoint protein Chfr is a ligase that ubiquitinates Plk1 and
RT   inhibits Cdc2 at the G2 to M transition.";
RL   J. Cell Biol. 156:249-259(2002).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, AUTOUBIQUITINATION, SUBCELLULAR
RP   LOCATION, AND DEVELOPMENTAL STAGE.
RX   PubMed=11912157;
RA   Chaturvedi P., Sudakin V., Bobiak M.L., Fisher P.W., Mattern M.R.,
RA   Jablonski S.A., Hurle M.R., Zhu Y., Yen T.J., Zhou B.-B.;
RT   "Chfr regulates a mitotic stress pathway through its RING-finger
RT   domain with ubiquitin ligase activity.";
RL   Cancer Res. 62:1797-1801(2002).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-244, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [9]
RP   VARIANTS ARG-270; VAL-497 AND MET-580, AND SILENCING IN PRIMARY
RP   CANCERS.
RX   PubMed=11948416; DOI=10.1038/sj.onc.1205402;
RA   Mizuno K., Osada H., Konishi H., Tatematsu Y., Yatabe Y.,
RA   Mitsudomi T., Fujii Y., Takahashi T.;
RT   "Aberrant hypermethylation of the CHFR prophase checkpoint gene in
RT   human lung cancers.";
RL   Oncogene 21:2328-2333(2002).
RN   [10]
RP   SILENCING IN PRIMARY CANCERS.
RX   PubMed=12538348; DOI=10.1093/carcin/24.1.47;
RA   Corn P.G., Summers M.K., Fogt F., Virmani A.K., Gazdar A.F.,
RA   Halazonetis T.D., El-Deiry W.S.;
RT   "Frequent hypermethylation of the 5' CpG island of the mitotic stress
RT   checkpoint gene Chfr in colorectal and non-small cell lung cancer.";
RL   Carcinogenesis 24:47-51(2003).
RN   [11]
RP   SILENCING IN PRIMARY CANCERS.
RX   PubMed=12810945; DOI=10.1073/pnas.1337066100;
RA   Toyota M., Sasaki Y., Satoh A., Ogi K., Kikuchi T., Suzuki H.,
RA   Mita H., Tanaka N., Itoh F., Issa J.-P.J., Jair K.-W., Schuebel K.E.,
RA   Imai K., Tokino T.;
RT   "Epigenetic inactivation of CHFR in human tumors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:7818-7823(2003).
RN   [12]
RP   SILENCING IN PRIMARY CANCERS.
RX   PubMed=14695171;
RA   Satoh A., Toyota M., Itoh F., Sasaki Y., Suzuki H., Ogi K.,
RA   Kikuchi T., Mita H., Yamashita T., Kojima T., Kusano M., Fujita M.,
RA   Hosokawa M., Endo T., Tokino T., Imai K.;
RT   "Epigenetic inactivation of CHFR and sensitivity to microtubule
RT   inhibitors in gastric cancer.";
RL   Cancer Res. 63:8606-8613(2003).
RN   [13]
RP   PHOSPHORYLATION, AND MUTAGENESIS OF THR-39 AND SER-205.
RX   PubMed=14638868;
RA   Shtivelman E.;
RT   "Promotion of mitosis by activated protein kinase B after DNA damage
RT   involves polo-like kinase 1 and checkpoint protein CHFR.";
RL   Mol. Cancer Res. 1:959-969(2003).
RN   [14]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH UBE2V2, AND
RP   PHOSPHORYLATION.
RX   PubMed=14562038; DOI=10.1038/sj.onc.1206831;
RA   Bothos J., Summers M.K., Venere M., Scolnick D.M., Halazonetis T.D.;
RT   "The Chfr mitotic checkpoint protein functions with Ubc13-Mms2 to form
RT   Lys63-linked polyubiquitin chains.";
RL   Oncogene 22:7101-7107(2003).
RN   [15]
RP   FUNCTION.
RX   PubMed=14694445; DOI=10.1002/mc.10161;
RA   Erson A.E., Petty E.M.;
RT   "CHFR-associated early G2/M checkpoint defects in breast cancer
RT   cells.";
RL   Mol. Carcinog. 39:26-33(2004).
RN   [16]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH PML.
RX   PubMed=15467728; DOI=10.1038/nsmb837;
RA   Daniels M.J., Marson A., Venkitaraman A.R.;
RT   "PML bodies control the nuclear dynamics and function of the CHFR
RT   mitotic checkpoint protein.";
RL   Nat. Struct. Mol. Biol. 11:1114-1121(2004).
RN   [17]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, DOMAIN PBZ-TYPE,
RP   POLY-ADP-RIBOSYLATION, ADP-RIBOSE-BINDING, AND MUTAGENESIS OF ARG-632;
RP   CYS-635; CYS-641; ARG-642 AND GLN-644.
RX   PubMed=18172500; DOI=10.1038/nature06420;
RA   Ahel I., Ahel D., Matsusaka T., Clark A.J., Pines J., Boulton S.J.,
RA   West S.C.;
RT   "Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint
RT   proteins.";
RL   Nature 451:81-85(2008).
RN   [18]
RP   DOMAIN FHA.
RX   PubMed=18335050; DOI=10.1371/journal.pone.0001776;
RA   Fukuda T., Kondo Y., Nakagama H.;
RT   "The anti-proliferative effects of the CHFR depend on the forkhead
RT   associated domain, but not E3 ligase activity mediated by ring finger
RT   domain.";
RL   PLoS ONE 3:E1776-E1776(2008).
RN   [19]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH HDAC1 AND HDAC2,
RP   AUTOUBIQUITINATION, AND MUTAGENESIS OF ILE-306.
RX   PubMed=19182791; DOI=10.1038/ncb1837;
RA   Oh Y.M., Kwon Y.E., Kim J.M., Bae S.J., Lee B.K., Yoo S.J.,
RA   Chung C.H., Deshaies R.J., Seol J.H.;
RT   "Chfr is linked to tumour metastasis through the downregulation of
RT   HDAC1.";
RL   Nat. Cell Biol. 11:295-302(2009).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 14-128.
RX   PubMed=12121644; DOI=10.1016/S0969-2126(02)00776-1;
RA   Stavridi E.S., Huyen Y., Loreto I.R., Scolnick D.M., Halazonetis T.D.,
RA   Pavletich N.P., Jeffrey P.D.;
RT   "Crystal structure of the FHA domain of the Chfr mitotic checkpoint
RT   protein and its complex with tungstate.";
RL   Structure 10:891-899(2002).
RN   [21]
RP   VARIANTS LEU-166; PRO-202 AND SER-536.
RX   PubMed=14612512;
RA   Mariatos G., Bothos J., Zacharatos P., Summers M.K., Scolnick D.M.,
RA   Kittas C., Halazonetis T.D., Gorgoulis V.G.;
RT   "Inactivating mutations targeting the chfr mitotic checkpoint gene in
RT   human lung cancer.";
RL   Cancer Res. 63:7185-7189(2003).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase that functions in the
CC       antephase checkpoint by actively delaying passage into mitosis in
CC       response to microtubule poisons. Acts in early prophase before
CC       chromosome condensation, when the centrosome move apart from each
CC       other along the periphery of the nucleus. Probably involved in
CC       signaling the presence of mitotic stress caused by microtubule
CC       poisons by mediating the 'Lys-48'-linked ubiquitination of target
CC       proteins, leading to their degradation by the proteasome. Promotes
CC       the ubiquitination and subsequent degradation of AURKA and PLK1.
CC       Probably acts as a tumor suppressor, possibly by mediating the
CC       polyubiquitination of HDAC1, leading to its degradation. May also
CC       promote the formation of 'Lys-63'-linked polyubiquitin chains and
CC       functions with the specific ubiquitin-conjugating UBC13-MMS2
CC       (UBE2N-UBE2V2) heterodimer. Substrates that are polyubiquitinated
CC       at 'Lys-63' are usually not targeted for degradation, but are
CC       rather involved in signaling cellular stress.
CC       {ECO:0000269|PubMed:10935642, ECO:0000269|PubMed:11807090,
CC       ECO:0000269|PubMed:11912157, ECO:0000269|PubMed:14562038,
CC       ECO:0000269|PubMed:14694445, ECO:0000269|PubMed:18172500,
CC       ECO:0000269|PubMed:19182791}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine. {ECO:0000269|PubMed:11807090,
CC       ECO:0000269|PubMed:11912157, ECO:0000269|PubMed:14562038,
CC       ECO:0000269|PubMed:18172500, ECO:0000269|PubMed:19182791}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts with HDAC1 and HDAC2. Interacts with PML (with
CC       sumoylated form of PML). {ECO:0000269|PubMed:14562038,
CC       ECO:0000269|PubMed:15467728, ECO:0000269|PubMed:19182791}.
CC   -!- SUBCELLULAR LOCATION: Nucleus, PML body
CC       {ECO:0000269|PubMed:11912157, ECO:0000269|PubMed:15467728,
CC       ECO:0000269|PubMed:18172500}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=Q96EP1-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q96EP1-2; Sequence=VSP_009349;
CC       Name=3;
CC         IsoId=Q96EP1-3; Sequence=VSP_009350;
CC       Name=4;
CC         IsoId=Q96EP1-4; Sequence=VSP_038127;
CC       Name=5;
CC         IsoId=Q96EP1-5; Sequence=VSP_038126;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. {ECO:0000269|PubMed:10935642}.
CC   -!- DEVELOPMENTAL STAGE: Weakly expressed in G1 phase, and highly
CC       expressed during S phase. {ECO:0000269|PubMed:11912157}.
CC   -!- DOMAIN: The PBZ-type zinc finger (also named CYR) mediates non-
CC       covalent poly(ADP-ribose)-binding. Poly(ADP-ribose)-binding is
CC       dependent on the presence of zinc and is required for its function
CC       in antephase checkpoint.
CC   -!- DOMAIN: The FHA domain plays a key role in the anti-proliferative
CC       properties of the protein and is involved in initiating a cell
CC       cycle arrest at G2/M. The FHA domain may be required to interact
CC       with phosphorylated proteins.
CC   -!- PTM: Poly-ADP-ribosylated. In addition to binding non covalently
CC       poly(ADP-ribose) via its PBZ-type zinc finger, the protein is also
CC       covalently poly-ADP-ribosylated by PARP1.
CC   -!- PTM: Autoubiquitinated; may regulate its cellular level.
CC       {ECO:0000269|PubMed:11807090, ECO:0000269|PubMed:11912157,
CC       ECO:0000269|PubMed:19182791}.
CC   -!- PTM: Phosphorylated by PKB. Phosphorylation may affect its E3
CC       ligase activity. {ECO:0000269|PubMed:14562038,
CC       ECO:0000269|PubMed:14638868}.
CC   -!- MISCELLANEOUS: CHFR is silenced in many primary cancers because of
CC       CpG methylation and deacetylated histones on its promoter region.
CC       This however raises the question of whether CHFR silencing is a
CC       consequence or a cause of primary cancers.
CC   -!- SIMILARITY: Belongs to the CHFR family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CHFRID526.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF170724; AAF91084.1; -; mRNA.
DR   EMBL; AK001658; BAA91817.1; -; mRNA.
DR   EMBL; AK027687; BAB55297.1; -; mRNA.
DR   EMBL; AK302785; BAG63989.1; -; mRNA.
DR   EMBL; AK304333; BAG65178.1; -; mRNA.
DR   EMBL; AC127070; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC012072; AAH12072.1; -; mRNA.
DR   EMBL; AL137561; CAB70812.1; -; mRNA.
DR   CCDS; CCDS31937.1; -. [Q96EP1-3]
DR   CCDS; CCDS53847.1; -. [Q96EP1-5]
DR   CCDS; CCDS53848.1; -. [Q96EP1-2]
DR   CCDS; CCDS53849.1; -. [Q96EP1-1]
DR   PIR; T46399; T46399.
DR   RefSeq; NP_001154816.1; NM_001161344.1. [Q96EP1-1]
DR   RefSeq; NP_001154817.1; NM_001161345.1. [Q96EP1-4]
DR   RefSeq; NP_001154818.1; NM_001161346.1. [Q96EP1-2]
DR   RefSeq; NP_001154819.1; NM_001161347.1. [Q96EP1-5]
DR   RefSeq; NP_060693.2; NM_018223.2. [Q96EP1-3]
DR   UniGene; Hs.720197; -.
DR   PDB; 1LGP; X-ray; 2.00 A; A=14-128.
DR   PDB; 1LGQ; X-ray; 2.10 A; A/B=14-124.
DR   PDB; 2XOC; X-ray; 1.89 A; A/B=407-664.
DR   PDB; 2XOY; X-ray; 2.60 A; A/B=407-664.
DR   PDB; 2XOZ; X-ray; 2.37 A; A/B=407-664.
DR   PDB; 2XP0; X-ray; 1.98 A; A/B=394-664.
DR   PDBsum; 1LGP; -.
DR   PDBsum; 1LGQ; -.
DR   PDBsum; 2XOC; -.
DR   PDBsum; 2XOY; -.
DR   PDBsum; 2XOZ; -.
DR   PDBsum; 2XP0; -.
DR   ProteinModelPortal; Q96EP1; -.
DR   SMR; Q96EP1; -.
DR   BioGrid; 120861; 45.
DR   DIP; DIP-40098N; -.
DR   IntAct; Q96EP1; 19.
DR   MINT; MINT-1381330; -.
DR   STRING; 9606.ENSP00000392395; -.
DR   iPTMnet; Q96EP1; -.
DR   PhosphoSitePlus; Q96EP1; -.
DR   BioMuta; CHFR; -.
DR   DMDM; 41688511; -.
DR   EPD; Q96EP1; -.
DR   MaxQB; Q96EP1; -.
DR   PaxDb; Q96EP1; -.
DR   PeptideAtlas; Q96EP1; -.
DR   PRIDE; Q96EP1; -.
DR   DNASU; 55743; -.
DR   Ensembl; ENST00000266880; ENSP00000266880; ENSG00000072609. [Q96EP1-3]
DR   Ensembl; ENST00000432561; ENSP00000392395; ENSG00000072609. [Q96EP1-1]
DR   Ensembl; ENST00000443047; ENSP00000416431; ENSG00000072609. [Q96EP1-5]
DR   Ensembl; ENST00000450056; ENSP00000398735; ENSG00000072609. [Q96EP1-2]
DR   GeneID; 55743; -.
DR   KEGG; hsa:55743; -.
DR   UCSC; uc001uld.3; human. [Q96EP1-1]
DR   CTD; 55743; -.
DR   DisGeNET; 55743; -.
DR   GeneCards; CHFR; -.
DR   HGNC; HGNC:20455; CHFR.
DR   HPA; HPA045768; -.
DR   MIM; 605209; gene.
DR   neXtProt; NX_Q96EP1; -.
DR   OpenTargets; ENSG00000072609; -.
DR   PharmGKB; PA134898949; -.
DR   eggNOG; KOG0802; Eukaryota.
DR   eggNOG; COG5243; LUCA.
DR   GeneTree; ENSGT00400000022306; -.
DR   HOVERGEN; HBG048005; -.
DR   InParanoid; Q96EP1; -.
DR   KO; K10644; -.
DR   OMA; ELAYQYR; -.
DR   OrthoDB; EOG091G03AR; -.
DR   PhylomeDB; Q96EP1; -.
DR   TreeFam; TF330957; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; CHFR; human.
DR   EvolutionaryTrace; Q96EP1; -.
DR   GeneWiki; CHFR; -.
DR   GenomeRNAi; 55743; -.
DR   PRO; PR:Q96EP1; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000072609; -.
DR   CleanEx; HS_CHFR; -.
DR   ExpressionAtlas; Q96EP1; baseline and differential.
DR   Genevisible; Q96EP1; HS.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IDA:UniProtKB.
DR   GO; GO:0000166; F:nucleotide binding; IDA:UniProtKB.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IEA:Ensembl.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0007093; P:mitotic cell cycle checkpoint; IMP:UniProtKB.
DR   GO; GO:0007067; P:mitotic nuclear division; IEA:UniProtKB-KW.
DR   GO; GO:0019941; P:modification-dependent protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IEA:Ensembl.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IEA:Ensembl.
DR   GO; GO:0031648; P:protein destabilization; IEA:Ensembl.
DR   GO; GO:0000209; P:protein polyubiquitination; IDA:UniProtKB.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IBA:GO_Central.
DR   CDD; cd00162; RING; 1.
DR   Gene3D; 3.30.40.10; -; 2.
DR   InterPro; IPR000253; FHA_dom.
DR   InterPro; IPR008984; SMAD_FHA_domain.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   Pfam; PF00498; FHA; 1.
DR   SMART; SM00240; FHA; 1.
DR   SMART; SM00184; RING; 1.
DR   SUPFAM; SSF49879; SSF49879; 1.
DR   PROSITE; PS50006; FHA_DOMAIN; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ADP-ribosylation; Alternative splicing; Cell cycle;
KW   Cell division; Complete proteome; Metal-binding; Mitosis; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome; Transferase;
KW   Ubl conjugation; Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN         1    664       E3 ubiquitin-protein ligase CHFR.
FT                                /FTId=PRO_0000055872.
FT   DOMAIN       38     89       FHA. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00086}.
FT   ZN_FING     304    343       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   ZN_FING     633    655       PBZ-type.
FT   MOD_RES     244    244       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     386    386       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q810L3}.
FT   VAR_SEQ     115    207       NVAYLYESLSEKQGMTQESFEANKENVFHGTKDTSGAGAGR
FT                                GADPRVPPSSPATQVCFEEPQPSTSTSDLFPTASASSTEPS
FT                                PAGRERSSSCG -> R (in isoform 5).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_038126.
FT   VAR_SEQ     135    146       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_009349.
FT   VAR_SEQ     136    206       ANKENVFHGTKDTSGAGAGRGADPRVPPSSPATQVCFEEPQ
FT                                PSTSTSDLFPTASASSTEPSPAGRERSSSC -> MVPCCVA
FT                                QAGLKLLGSSDPPTLASQSIVIT (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_009350.
FT   VAR_SEQ     470    470       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_038127.
FT   VARIANT     166    166       P -> L (in a patient with non small cell
FT                                lung carcinomas; homozygous).
FT                                {ECO:0000269|PubMed:14612512}.
FT                                /FTId=VAR_017582.
FT   VARIANT     202    202       R -> P (in a patient with non small cell
FT                                lung carcinomas).
FT                                {ECO:0000269|PubMed:14612512}.
FT                                /FTId=VAR_017583.
FT   VARIANT     270    270       G -> R (in dbSNP:rs115096950).
FT                                {ECO:0000269|PubMed:11948416}.
FT                                /FTId=VAR_017584.
FT   VARIANT     497    497       A -> V (common polymorphism;
FT                                dbSNP:rs2306541).
FT                                {ECO:0000269|PubMed:11948416,
FT                                ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_017585.
FT   VARIANT     536    536       F -> S (in a patient with non small cell
FT                                lung carcinomas).
FT                                {ECO:0000269|PubMed:14612512}.
FT                                /FTId=VAR_017586.
FT   VARIANT     580    580       V -> M (common polymorphism;
FT                                dbSNP:rs2306536).
FT                                {ECO:0000269|PubMed:10935642,
FT                                ECO:0000269|PubMed:11948416,
FT                                ECO:0000269|PubMed:14702039}.
FT                                /FTId=VAR_017587.
FT   MUTAGEN      39     39       T->A: Abolishes phosphorylation but not
FT                                autoubiquitination; when associated with
FT                                A-205. {ECO:0000269|PubMed:14638868}.
FT   MUTAGEN     205    205       S->A: Abolishes phosphorylation but not
FT                                autoubiquitination; when associated with
FT                                A-39. {ECO:0000269|PubMed:14638868}.
FT   MUTAGEN     306    306       I->A: Abolishes autoubiquitination. Does
FT                                not affect phosphorylation.
FT                                {ECO:0000269|PubMed:11807090,
FT                                ECO:0000269|PubMed:19182791}.
FT   MUTAGEN     332    332       W->A: Abolishes autoubiquitination in
FT                                vitro. {ECO:0000269|PubMed:11807090}.
FT   MUTAGEN     632    632       R->A: Abolishes poly(ADP-ribose)-binding
FT                                and poly-ADP-ribosylation by PARP1.
FT                                {ECO:0000269|PubMed:18172500}.
FT   MUTAGEN     635    635       C->A: Abolishes poly(ADP-ribose)-binding
FT                                and poly-ADP-ribosylation by PARP1; when
FT                                associated with A-641.
FT                                {ECO:0000269|PubMed:18172500}.
FT   MUTAGEN     641    641       C->A: Abolishes poly(ADP-ribose)-binding
FT                                and poly-ADP-ribosylation by PARP1; when
FT                                associated with A-635.
FT                                {ECO:0000269|PubMed:18172500}.
FT   MUTAGEN     642    642       R->A: Impairs poly(ADP-ribose)-binding
FT                                and poly-ADP-ribosylation by PARP1.
FT                                {ECO:0000269|PubMed:18172500}.
FT   MUTAGEN     644    644       Q->A: Impairs poly(ADP-ribose)-binding
FT                                and poly-ADP-ribosylation by PARP1.
FT                                {ECO:0000269|PubMed:18172500}.
FT   CONFLICT    256    256       V -> E (in Ref. 2; BAA91817).
FT                                {ECO:0000305}.
FT   CONFLICT    462    462       S -> P (in Ref. 2; BAA91817).
FT                                {ECO:0000305}.
FT   CONFLICT    599    599       V -> A (in Ref. 2; BAG65178).
FT                                {ECO:0000305}.
FT   CONFLICT    617    617       R -> Q (in Ref. 2; BAA91817).
FT                                {ECO:0000305}.
FT   STRAND       17     19       {ECO:0000244|PDB:1LGP}.
FT   STRAND       26     28       {ECO:0000244|PDB:1LGP}.
FT   STRAND       31     33       {ECO:0000244|PDB:1LGP}.
FT   STRAND       35     43       {ECO:0000244|PDB:1LGP}.
FT   STRAND       46     49       {ECO:0000244|PDB:1LGP}.
FT   STRAND       61     65       {ECO:0000244|PDB:1LGP}.
FT   TURN         67     69       {ECO:0000244|PDB:1LGP}.
FT   STRAND       72     76       {ECO:0000244|PDB:1LGP}.
FT   STRAND       78     80       {ECO:0000244|PDB:1LGP}.
FT   STRAND       82     90       {ECO:0000244|PDB:1LGQ}.
FT   STRAND       92     96       {ECO:0000244|PDB:1LGQ}.
FT   STRAND      102    106       {ECO:0000244|PDB:1LGP}.
FT   HELIX       112    114       {ECO:0000244|PDB:1LGP}.
FT   STRAND      116    119       {ECO:0000244|PDB:1LGP}.
FT   HELIX       433    436       {ECO:0000244|PDB:2XOC}.
FT   STRAND      482    484       {ECO:0000244|PDB:2XOC}.
FT   TURN        486    488       {ECO:0000244|PDB:2XOC}.
FT   STRAND      491    493       {ECO:0000244|PDB:2XOC}.
FT   HELIX       496    500       {ECO:0000244|PDB:2XOC}.
FT   TURN        511    513       {ECO:0000244|PDB:2XOC}.
FT   HELIX       519    522       {ECO:0000244|PDB:2XOC}.
FT   STRAND      532    535       {ECO:0000244|PDB:2XOC}.
FT   HELIX       536    538       {ECO:0000244|PDB:2XOC}.
FT   TURN        543    552       {ECO:0000244|PDB:2XOC}.
FT   HELIX       554    566       {ECO:0000244|PDB:2XOC}.
FT   HELIX       571    583       {ECO:0000244|PDB:2XOC}.
FT   STRAND      599    601       {ECO:0000244|PDB:2XOC}.
FT   HELIX       602    618       {ECO:0000244|PDB:2XOC}.
FT   HELIX       622    624       {ECO:0000244|PDB:2XOC}.
FT   HELIX       627    630       {ECO:0000244|PDB:2XOC}.
FT   HELIX       638    640       {ECO:0000244|PDB:2XOC}.
FT   HELIX       643    645       {ECO:0000244|PDB:2XP0}.
FT   HELIX       647    652       {ECO:0000244|PDB:2XOC}.
SQ   SEQUENCE   664 AA;  73386 MW;  141A1E7FEFAE36A2 CRC64;
     MERPEEGKQS PPPQPWGRLL RLGAEEGEPH VLLRKREWTI GRRRGCDLSF PSNKLVSGDH
     CRIVVDEKSG QVTLEDTSTS GTVINKLKVV KKQTCPLQTG DVIYLVYRKN EPEHNVAYLY
     ESLSEKQGMT QESFEANKEN VFHGTKDTSG AGAGRGADPR VPPSSPATQV CFEEPQPSTS
     TSDLFPTASA SSTEPSPAGR ERSSSCGSGG GGISPKGSGP SVASDEVSSF ASALPDRKTA
     SFSSLEPQDQ EDLEPVKKKM RGDGDLDLNG QLLVAQPRRN AQTVHEDVRA AAGKPDKMEE
     TLTCIICQDL LHDCVSLQPC MHTFCAACYS GWMERSSLCP TCRCPVERIC KNHILNNLVE
     AYLIQHPDKS RSEEDVQSMD ARNKITQDML QPKVRRSFSD EEGSSEDLLE LSDVDSESSD
     ISQPYVVCRQ CPEYRRQAAQ PPHCPAPEGE PGAPQALGDA PSTSVSLTTA VQDYVCPLQG
     SHALCTCCFQ PMPDRRAERE QDPRVAPQQC AVCLQPFCHL YWGCTRTGCY GCLAPFCELN
     LGDKCLDGVL NNNSYESDIL KNYLATRGLT WKNMLTESLV ALQRGVFLLS DYRVTGDTVL
     CYCCGLRSFR ELTYQYRQNI PASELPVAVT SRPDCYWGRN CRTQVKAHHA MKFNHICEQT
     RFKN
//
